Slide 1: Q2 2023 Financial Results
Q2 2023 Financial Results August 10, 2023 © 2023 Forian Inc. All rights reserved. 1
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In
Slide 3: Revenue and Adjusted EBITDA
Revenue and Adjusted EBITDA QTR Ended June 30, (in 000's) YTD June 30, (in 000's) 2023 2022 2023 2022 Unaudited Unaudited Change % Unaudited Unaudited Change % Total revenue $ 4,894 $ 3,603 36% $ 9,764 $ 7,138 37% Loss from continuing operations, net of tax $ (1,090) $ (4,008) 73% $ (3,876) $ (14,32
Slide 4: Healthcare Information Revenue Trend
Healthcare Information Revenue Trend 36% Q2 2023 revenue growth over same quarter last year 37% Q2 2023 revenue growth over same period YTD last year © 2023 Forian Inc. All rights reserved. 4
Slide 5: Costs and Expenses
Costs and Expenses Focused business model drives cost reductions: • 15% decrease in Q2 2023 Costs and Expenses • 36% decrease in YTD Q2 2023 Costs and Expenses © 2023 Forian Inc. All rights reserved. 5
Slide 6: Adjusted EBITDA – continuing operations
Adjusted EBITDA – continuing operations Continued improvement in Adjusted EBITDA driven by revenue growth and cost management Adjusted EBITDA is a non-U.S. GAAP measure. See Appendix for further information, including a reconciliation of Adjusted EBITDA to Net Loss. © 2023 Forian Inc. All rights res
Slide 7: Full Year 2023 Outlook
Full Year 2023 Outlook Expect 2023 Healthcare Information Revenue growth of 25% to 37% resulting in revenue in the range of $20.5 to $22.5 million Continued Improvement in Adjusted EBITDA, with a positive Adjusted EBITDA contribution in the second half of 2023 The outlook provided above constitutes
Slide 8: Summary Balance Sheet Data $000’s
Summary Balance Sheet Data $000’s June 30, 2023 Cash and equivalents $41,247 Proceeds receivable – sale of discontinued operations $ 6,502 Net working capital $46,036 Convertible note and accrued interest (due 9/2025) $25,526 Shares outstanding 32,452 © 2023 Forian Inc. All rights reserved. 8
Slide 9: Q&A
Q&A © 2023 Forian Inc. All rights reserved. 9
Slide 10: Appendix
Appendix © 2023 Forian Inc. All rights reserved. 10
Slide 11: Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
Reconciliation of U.S. GAAP to Non-GAAP Financial Measures This presentation includes a non-GAAP measure, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-U.S. GAAP financial measure provided herein is earnings before interest, taxes, non-cash
Slide 12: Non-U.S. GAAP Reconciliations Reported Net Income to Adjusted EBITDA
Non-U.S. GAAP Reconciliations Reported Net Income to Adjusted EBITDA For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Total revenues $ 4,893,542 $ 3,602,913 $ 9,763,929 $ 7,137,774 Net loss from continuing operations $ (1,090,400) $ (4,008,132) $ (3,339,199)
Slide 13: © 2023 Forian Inc. All rights reserved.
© 2023 Forian Inc. All rights reserved.